Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01784536 · ClinicalTrials.gov registry record · Phase 1
Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers
A Phase 1 study, sponsored by Melinta Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01784536 is a Phase 1 study that has completed, run by Melinta Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT01784536, a Phase 1 study, has completed, sponsored by Melinta Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.
Interventions
- DRUG Single-Dose IV Oritavancin Diphosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-01 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01784536
The ClinicalTrials.gov registry entry for NCT01784536 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Melinta Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Single-Dose IV Oritavancin Diphosphate is the first listed.
NCT01784536 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01784536 about?
NCT01784536 is a clinical study titled "Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers". The purpose of this study is to examine the effects of oritavancin on the in vivo activities of CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, NAT 2, and XO using a Cooperstown 5 + 1 cocktail in an open label, single arm manner.
What is the current status of trial NCT01784536?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-01. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01784536?
The interventions under investigation include: Single-Dose IV Oritavancin Diphosphate (DRUG).
Who is sponsoring clinical trial NCT01784536?
This trial is sponsored by Melinta Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.